The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...

But is the combination a "viable alternative" to nivolumab and ipilimumab?

Sofetabart mipitecan received FDA breakthrough therapy designation for platinum-resistant ovarian cancer after prior ...

Recent advancements include targeted agents, immunotherapy, and fertility-sparing surgeries for patients with advanced ...

Shares of Corcept Therapeutics CORT were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, ...

Eye drop nanoparticles that shrink over time overcome the eye's natural defenses, delivering protein drugs to the retina and ...

Shares of CytomX Therapeutics CTMX were up 30.8% this past month after it announced strategic business updates and outlined ...

Eli Lilly and Company LLY announced that the FDA has granted a Breakthrough Therapy designation to its novel folate receptor alpha (FRα) antibody-drug conjugate (ADC), sofetabart mipitecan (LY4170156) ...

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients with BRAF V600E mCRC.

As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...

Data from the COMMIT trial demonstrated that the addition of oxaliplatin, leucovorin, 5-fluorouracil (mFOLFOX6) and ...

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...